Evidence map›Paper›PMID 18978304›Full record

ArticleAmerican journal of respiratory cell and molecular biology2009

Oncostatin M regulates secretoglobin 3A1 and 3A2 expression in a bidirectional manner.

Takeshi Tomita, Atsushi Yamada, Masaaki Miyakoshi, Taketomo Kido, Faruk Sheikh, Achara Srisodsai, Atsushi Miyajima, Raymond P Donnelly, Shioko Kimura

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Preclinical evaluation of human secretoglobin 3A2 in mouse models of lung development and fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2014
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Takeshi TomitaLaboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Atsushi Yamada
Masaaki Miyakoshi
Taketomo Kido
Faruk Sheikh
Achara Srisodsai
Atsushi Miyajima
Raymond P Donnelly
Shioko Kimura
National Institutes of Health · USCenter for Drug Evaluation and Research · USThe University of Tokyo · JP

Funding

Role of Novel Cytokine Secretoglobin (SCGB) 3A2 in LungZIABC010449 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KIMURA, SHIOKO · 2009 to 2025
$10.3M
Uteroglobin-Related Protein (UGRP) 1 in Lung InflammatioZ01BC010449 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KIMURA, SHIOKO · 2002 to 2008
$594k
Intramural NIH HHS Z01 BC010449Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Secretoglobin (SCGB) 3A1 and 3A2 are members of the small molecular weight secretoglobin gene superfamily. SCGB3A1 is a tumor suppressor gene, whereas SCGB3A2 has anti-inflammatory properties. Both genes are mainly expressed in the lung and trachea in mice. Whether the expression and/or function of these two genes are related is not known. Here we show that the expression of SCGB3A1 and SCGB3A2 are bidirectionally regulated by oncostatin M (OSM) when examined in a mouse transformed Clara cell line (mtCC); SCGB3A1 is up-regulated by OSM, while SCGB3A2 is down-regulated in a time- and dose-dependent manner. OSM-activated STAT3/5, through binding to the STAT-binding element located at -201 to -209 bp in the mouse Scgb3a1 gene promoter, and the extracellular signal-regulated kinase (ERK)- and p38-mitogen-activated protein kinase (MAPK) pathways are responsible for the OSM-induced up-regulation of SCGB3A1 expression. On the other hand, the -113 to -273 bp region in the Scgb3a2 promoter appears to be responsible for the OSM induced down-regulation of the gene. No significant differences in the levels or patterns of specific DNA-binding proteins were found in the -113 to -273 bp region as determined by electrophoretic mobility shift assays. Neither the ERK- nor p38-MAPK pathways were involved in the OSM-induced reduction of Scgb3a2 promoter activity. These results suggest that OSM-induced suppression of SCGB3A2 expression is an indirect effect of OSM. Expression of the Clara cell marker, CYP2F2, was markedly decreased upon OSM treatment in parallel with the decrease of SCGB3A2 expression in mtCC cells. The differential regulation of Scgb3a1 and Scgb3a2 gene expression by OSM may explain the unique functions of these genes in the lung.

Indexed as

AnimalsBase SequenceGene Expression RegulationMAP Kinase Signaling SystemMiceMice, Inbred C57BLMolecular Sequence DataNIH 3T3 CellsOncostatin MPhenotypeProtein BindingProteinsRespiratory SystemResponse ElementsRNA, MessengerSecretoglobinsOncostatin MProteinsRNA, MessengerScgb3a2 protein, mouseSecretoglobinsSTAT Transcription FactorsUGRP2 protein, mouse

Identifiers

PMID18978304
PMCPMC2677441
OpenAlexW1995722962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.